Skip to main content
Top
Published in: Clinical Rheumatology 7/2009

01-07-2009 | Case Report

Systemic mastocytosis presenting as osteoporosis—a case report

Authors: R. Mathew, V. Dhillon, P. Shepherd

Published in: Clinical Rheumatology | Issue 7/2009

Login to get access

Abstract

Mastocytosis is a clonal disorder of the mast cell and its precursor cells, and is characterised by proliferation and accumulation of mast cells within various organs, most commonly the skin. Systemic mastocytosis is a rare but well-recognised cause of secondary osteoporosis, accounting for about 1.25% of cases. The pathophysiological mechanism is probably multifactorial, including increased osteoclastic activity, and a direct effect of mast cell mediators like histamine, heparin, tryptase and cytokines. Here, we report the case of a middle-aged male patient with osteoporotic vertebral fractures as a rare presenting manifestation of systemic mastocytosis. In summary, systemic mastocytosis, although rare, should be considered as a cause in patients with idiopathic osteoporosis.
Literature
1.
go back to reference Pardanani A, Akin C, Valent P (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 19(3):595–615PubMedCrossRef Pardanani A, Akin C, Valent P (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 19(3):595–615PubMedCrossRef
2.
go back to reference Delling G, Ritzel H, Werner M (2001) Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis, A retrospective analysis of 158 cases. Pathologe 22(2):132–140PubMedCrossRef Delling G, Ritzel H, Werner M (2001) Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis, A retrospective analysis of 158 cases. Pathologe 22(2):132–140PubMedCrossRef
3.
go back to reference Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36(1):32–36PubMedCrossRef Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36(1):32–36PubMedCrossRef
4.
go back to reference Dobigny C, Saffar JL (1997 Oct) H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol 173(1):10–18PubMedCrossRef Dobigny C, Saffar JL (1997 Oct) H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol 173(1):10–18PubMedCrossRef
5.
go back to reference Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906–3915PubMedCrossRef Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906–3915PubMedCrossRef
6.
go back to reference Lim AYN, Ostor AJK, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966PubMedCrossRef Lim AYN, Ostor AJK, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966PubMedCrossRef
7.
go back to reference Lehman T, Beyeler C (1996) Severe osteoporosis due to systemic mast cell disease: successful treatment with Interferon alpha 2B. Br J Rheumatol 35:898–900CrossRef Lehman T, Beyeler C (1996) Severe osteoporosis due to systemic mast cell disease: successful treatment with Interferon alpha 2B. Br J Rheumatol 35:898–900CrossRef
Metadata
Title
Systemic mastocytosis presenting as osteoporosis—a case report
Authors
R. Mathew
V. Dhillon
P. Shepherd
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1165-4

Other articles of this Issue 7/2009

Clinical Rheumatology 7/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.